BioMarin Pharmaceutical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

BioMarin Pharmaceutical hat ein Gesamteigenkapital von $5.1B und eine Gesamtverschuldung von $1.1B, wodurch sich der Verschuldungsgrad auf 21.4% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $6.9B bzw. $1.8B. BioMarin Pharmaceutical Das EBIT des Unternehmens beträgt $188.2M, so dass der Zinsdeckungsgrad -3.9 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $1.0B.

Wichtige Informationen

21.4%

Verhältnis von Schulden zu Eigenkapital

US$1.09b

Verschuldung

Zinsdeckungsgrad	-3.9x
Bargeld	US$1.05b
Eigenkapital	US$5.07b
Gesamtverbindlichkeiten	US$1.80b
Gesamtvermögen	US$6.87b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25

Recent updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Jun 01

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Apr 21

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Mar 30

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Jan 19

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Jan 05

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Dec 15

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Nov 03

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Aug 09

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Jul 18

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 09

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Apr 18

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25

BioMarin: A Good Anchor For Your Biotech Portfolio

May 10

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BMRNDie kurzfristigen Aktiva des Unternehmens ($3.0B) übersteigen seine kurzfristigen Passiva ($1.1B).

Langfristige Verbindlichkeiten: BMRNDie kurzfristigen Vermögenswerte des Unternehmens ($3.0B) übersteigen seine langfristigen Verbindlichkeiten ($711.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BMRNDie Nettoverschuldung im Verhältnis zum Eigenkapital (0.8%) wird als zufriedenstellend angesehen.

Schulden abbauen: BMRN Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 28.4% auf 21.4% zurückgegangen.

Schuldendeckung: BMRNDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (25.8%).

Zinsdeckung: BMRN mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

BioMarin Pharmaceutical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

Recent updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Executive VP notifies of intention to sell stock

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

Director notifies of intention to sell stock

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 17%

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Insider recently sold US$3.0m worth of stock

Insider notifies of intention to sell stock

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Director notifies of intention to sell stock

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

Director notifies of intention to sell stock

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Biomarin Pharmaceutical Inc. Announces CEO Changes

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe

Executive VP recently sold US$984k worth of stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc

U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 13%

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Independent Director notifies of intention to sell stock

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Chairman & CEO notifies of intention to sell stock

Executive VP & Chief Legal Officer exercised options to buy US$148k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 32%

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Executive VP of Finance & CFO exercised options and sold US$129k worth of stock

Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its Type II Variation Application to Extend the Indication for VOXZOGO® (Vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 2

BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program

BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022

FDA Accepts Biomarin's Biologics License Application (Bla) for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults with Severe Hemophilia A

BioMarin redesigns organization, will lay off about 4% of its workforce

BioMarin Pharmaceutical Inc. to Report Q3, 2022 Results on Oct 26, 2022

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

BioMarin Pharmaceutical Inc. Announces First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN(TM) (valoctocogene roxaparvovec), Approved by European Commission (EC)